ADVANCES IN Cancer IMMUNOTHERAPY™

Identification and Management of Immune-Related Adverse Events in the Emergency Setting

Leslie S Zun, MD, MBA, FAAEM
Professor and Chair, Department of Emergency Medicine
Chicago Medical School
North Chicago, Illinois

American Academy of Emergency Medicine

ACCC
Association of Community Cancer Centers

sitc
Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Disclosures

- Eisai Co., Ltd., Genentech, Inc., Novartis AG, Pfizer, Consulting Fees (example of financial relationship listing from COI form)
- If no conflicts state: No relevant financial relationships to disclose
- I will be discussing non-FDA approved indications during my presentation.

Association of Community Cancer Centers

Society for Immunotherapy of Cancer

CTLA-4 and PD-1/PD-L1
Immune checkpoint mechanisms

- Involved in maintaining appropriate immune response
- Downregulates & prevents inappropriate activity
- Autoimmune type response
- Thinking “Chemo” will lead to incorrect AE strategy
- **Immunotherapy AEs similar to Graft versus Host disease**

Timing of irAE incidence

- Most irAEs occur within three months of treatment initiation
- irAEs can occur past treatment completion
- Some irAEs are dose-dependent
- ~10% of overall irAEs grade 3/4

Timing of irAE incidence



Timing of irAE incidence



irAE Grades

1 Asymptomatic
2 Symptomatic
3 Severe symptoms
4 Life-threatening

- Treatment depends on grade
- 1 • Corticosteroids not usually indicated
  - • Continue immunotherapy
- 2 • If indicated, start oral prednisone 0.5-1 mg/kg/day if patients can take oral medication. •
  - Hold immunotherapy during corticosteroid use
- 3 • Start prednisone 1-2 mg/kg/day.
  - Hold immunotherapy;
- 4 • Start prednisone 1-2 mg/kg/day).
  - Discontinue immunotherapy

irAE Treatment

- Corticosteroids
  - **Prednisone**
  - Dexamethasone
  - Methylprednisolone
  - Hydrocortisone
  - Cortisone
- Mycophenolate mofetil (CellCept)
  - Standard BID
- TNF inhibitors
  - Infliximab
  - Adalimumab
  - Others

Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Dermatologic Toxicity
Diarrhea/ Colitis
Hepatitis
Endocrinopathies
Pneumonitis
Pancreatic irAEs
Renal insufficiency
Opthalmolgic irAEs
Rare irAEs

Association of Community Cancer Centers

Society for Immunotherapy of Cancer

Dermatologic toxicity presentations

- Often presents ~ three weeks post-therapy initiation
- Mild – maculopapular rash with or without symptoms
  - Pruitis, burning, tightness
  - 10% - 30% TBSA
  - Limiting ADL's
  - Topical steroids, hydroxyzine, diphenhydramine
  - Cort
- Moderate – diffuse, nonlocalizing rash
  - 30% - 50% TBSA
  - Topical corticosteroids, hydroxyzine, diphenhydramine
  - Consider systemic corticosteroids if no improvement within one week (0.5 – 1mg/kg/day)

Dermatologic toxicity presentation

- Severe
  - Blisters, dermal ulceration, necrotic, bullous or hemorrhagic
  - Systemic corticosteroids 1 – 2mg/kg/day prednisone equivalent
  - Taper over one month following improvement

- Vitiligo
  - Most cases permanant
  - No treatment
  - Intra oral lesions – consider candidiasis

Stevens Johnsons Syndrome (SJS)/ TEN (Toxic Epidermal Necrolysis)







Vitiligo

Diarrhea/ colitis presentation

- Mild - <4 stools above baseline/day

- Treatment
  - Symptomatic: oral hydration & bland diet
  - No corticosteroids
  - Avoid medications
  - Budesonide – no significant difference

Diarrhea/ colitis presentation

- Moderate – 4-6 stools above daily baseline
  - Abdominal pain, blood or mucus in stool
  - Testing – *C. diff*, lactoferrin, O & P, stool Cx
  - Systemic corticosteroids 0.5mg/kg/day prednisone equivalent if symptoms persist > one week

Diarrhea/ colitis presentation

- Severe – >6 stools above daily baseline
  - Peritoneal signs, ileus or fever
  - Admission
  - IV hydration
  - Rule out perforation
  - Stool studies

Diarrhea/ colitis presentation

- Severe – >6 stools above daily baseline
  - Systemic corticosteroids 1-2mg/kg/day equivalent, if no perforation
    - Hold if clinically stable until stool studies available (24hrs)
  - Unstable – High dose corticosteroids: methylprednisolone 125 mg IV daily x 3 days to evaluate responsiveness
  - Consider empiric antibiotics for fever or leukocytosis
  - Infliximab 5 mg/kg if non responsive to corticosteroids
  - Consider mycophenolate mofetil for select patients

Hepatotoxicity presentation

- 8 -12 weeks after therapy initiation
- Grade 2 toxicity
  - 2.5< AST/ALT <5 times ULN
  - 1.5< Bilirubin<3 times ULN
  - Corticosteroids 0.5-1 mg/kg/day & 1 mo. taper
- Grade ≥3 toxicity
  - Admission
  - Methylprednisolone IV 125mg/day
  - Consider mycophenolate mofetil 500mg PO Q12hrs
- Avoid alcohol & acetaminophen

Endocrinopathy presentations

- >10% all reported irAE cases
- Can arise while receiving checkpoint inhibitors
- Hypophysitis
  - 1-2 months after initiation of therapy
  - Fatigue, headaches, visual field defects
  - ACTH, TSH, FSH, LH, GH, prolactin
  - Imaging – enlarged pituitary gland
  - Corticosteroids 1 mg/kg/day, or IV dexamethasone 6 mg Q6hr x 3 days, or methylprednisolone 125 mg daily

Endocrinopathy presentation

- Hypothyroidism
  - 1 wk-19 months onset after therapy initiation
  - Appropriate levothyroxine replacement
- Hyperthyroidism
  - Check TSH level
  - Acute thyroiditis secondary to immune activation
    - Corticosteroids 1 mg/kg for symptomatic patients
- Adrenal Insufficiency
  - Admission
  - Corticosteroids 60-80 mg prednisone or equivalent

Pneumonitis presentation

- Can arise during treatment with checkpoint inhibitors
- Symptomatic ~ 5 months after treatment initiation
- New cough or dyspnea
- Multiple grades
  - Grade 2
    - Admission
    - Prednisone/prednisolone
      - Taper over one month after improvement seen
  - Grade 3-4
    - Admission
    - Prednisone/prednisolone
      - Taper over six weeks

Pneumonitis presentation



Pancreatic irAE presentations

- Elevated amylase and/or lipase
  - Can arise during treatment with checkpoint inhibitors
  - Without overt pancreatitis – monitor patient
  - Symptomatic Grade 3/4 incidences – hold therapy

- New onset diabetes with diabetic ketoacidosis
  - Normal ED treatment
  - Aggressive treatment of DKA

Renal insufficiency presentation

- <1% of overall irAE cases
- 10-12 months after initiation of treatment
- Grade 1: up to 1.5x baseline
- Grade 2/3: 1.5 - 6x baseline
- Full recovery with high dose corticosteroids.
  - (>40 mg/day)

Opthalmologic irAE presentations

- <1% of overall irAE cases
- Episcleritis
- Uveitis
- Conjunctivitis
- Topical corticosteroids – prednisolone acetate 1%

Opthalmologic irAE presentation



Opthalmologic irAE presentation



Opthalmologic irAE presentation

Rare irAE presentations

- <1% of overall irAE cases
  - Red cell aplasia
  - Thrombocytopenia
  - Hemophilia A
  - Gullian-Barre syndrome
  - Myasthenia gravis
  - Posterior reversible encephalopathy syndrome
  - Aseptic meningitis
  - Transverse myelitis
  - ??

Questions

- Contact info

- Leslie Zun
- leszun@gmail.com
- 773-426-3763